Comparative bioavailability of two brands of ciprofloxacin.

Simple item page
dc.contributor.authorSeth, S Den_US
dc.contributor.authorBeotra, Aen_US
dc.contributor.authorSeth, Sen_US
dc.date.accessioned1995-05-01en_US
dc.date.accessioned2009-05-30T23:57:11Z
dc.date.available1995-05-01en_US
dc.date.available2009-05-30T23:57:11Z
dc.date.issued1995-05-01en_US
dc.description.abstractTwelve adult healthy volunteers participated on two occasions in a cross-over study with an interval of 30 days. The bioavailability of ciprofloxacin 500 mg administered as single oral dose was compared in preparation A (Indian, Torrent) and preparation B (Imported, Bayer). The drug was administered early morning on an empty stomach. Blood samples were collected at 1/2,1,2,4,6,8,12 and 24 hours. Plasma levels of ciprofloxacin were determined by HPLC. Time taken to achieve peak plasma concentration (Tmax) was 2 hours (A) and 1.67 +/- 0.49 hours (B). Maximum plasma concentration (Cmax) ranged from 1.8 to 5.1 ug/ml (mean 3.08 +/- 0.99 ug/ml) for 'A' and 2.08 to 5.5 mu g/ml (mean 3.58 +/- 1.37 mu g/me for 'B'. Area under plasma concentration time curve ranged from 30.91 to 118.27 ug/ml/hr (mean 59.97 +/- 26.68 ug/ml/hr) in 'A' and 36.52 to 108.05 (mean 62.80 +/- 22.33 ug/ml/hr) in 'B' which is more than reported in Western literature. Large bioavailability of ciprofloxacin in the present study suggests the need to be cautious while treating patients with renal problems and to use lower doses in Indian patients to achieve desirable results. However, there was no significant difference in the pharmacokinetic parameters between the two brands (Paired 't' test and Wilcoxon Sign Rank test). It is therefore, concluded that both the preparations are comparable in terms of bioavailability.en_US
dc.description.affiliationDepartment of Pharmacology, All India Institute of Medical Sciences, New Delhi.en_US
dc.identifier.citationSeth SD, Beotra A, Seth S. Comparative bioavailability of two brands of ciprofloxacin. Journal of the Association of Physicians of India. 1995 May; 43(5): 327-30en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/90879
dc.language.isoengen_US
dc.source.urihttps://www.japi.orgen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdulten_US
dc.subject.meshAnti-Infective Agents --administration & dosageen_US
dc.subject.meshBiological Availabilityen_US
dc.subject.meshCiprofloxacin --administration & dosageen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshHumansen_US
dc.subject.meshIndiaen_US
dc.subject.meshMaleen_US
dc.subject.meshMetabolic Clearance Rate --physiologyen_US
dc.titleComparative bioavailability of two brands of ciprofloxacin.en_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Association of Physicians of India